Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552360 | 0.79 | NPC1 (0.42) | NPC1RAB9ANOTUMTP53SMN1; SMN2 | |
| SCHEMBL3965118 | 0.79 | LMNA (0.44) | NPC1RAB9ANOTUMSMN1; SMN2HSD17B10 | |
| SCHEMBL6135425 | 0.75 | RAB9A (0.46) | NPC1RAB9ANOTUMTP53SMN1; SMN2 | |
| SCHEMBL5548958 | 0.75 | NOTUM (0.49) | NOTUMMAOAMAOB | |
| SCHEMBL2333242 | 0.75 | NPC1 (0.47) | NPC1RAB9ANOTUMTP53SMN1; SMN2 | |
| SCHEMBL4773008 | 0.68 | NPC1 (0.46) | NPC1RAB9ANOTUMTP53SMN1; SMN2 | |
| SCHEMBL4159658 | 0.67 | CHRNB2 (0.51) | NPC1RAB9ATP53SMN1; SMN2TSHR | |
| SCHEMBL5543822 | 0.67 | NPC1 (0.48) | NPC1RAB9ANOTUMTP53SMN1; SMN2 | |
| SCHEMBL19347424 | 0.67 | RAB9A (0.40) | NPC1RAB9ANOTUMSMN1; SMN2KDM4E | |
| SCHEMBL5553581 | 0.66 | NPC1 (0.50) | NPC1RAB9ANOTUMTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372626-B | Method for preparing 1,2, 4-oxadiazole compound | 河南大学 | 2022-11-08 | — | — | CN | claimed |
| EP-1789053-B1 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES INC (US) | 2012-06-13 | — | — | EP | claimed |
| US-20100105706-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO, INC. (US) | 2010-04-29 | — | — | US | claimed |
| CN-100467469-C | A2BAdenosine receptor antagonists | CV THERAPEUTICS INC (US) | 2009-03-11 | — | — | CN | claimed |
| CN-101043889-A | Using A2BMethod of promoting wound healing with adenosine receptor antagonists | CV THERAPEUTICS INC (US) | 2007-09-26 | — | — | CN | claimed |
| CN-101039677-A | Using A2BMethod for preventing and treating airway remodeling and pulmonary inflammation by adenosine receptor antagonist | CV THERAPEUTICS INC (US) | 2007-09-19 | — | — | CN | claimed |
| EP-1799221-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-06-27 | — | — | EP | claimed |
| EP-1789053-A2 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-05-30 | — | — | EP | claimed |
| US-7105665-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2006-09-12 | — | — | US | claimed |
| US-20060159627-A1 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-07-20 | — | — | US | claimed |
| WO-2006044610-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC (US) | 2006-04-27 | — | — | WO | claimed |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-03-16 | — | — | US | claimed |
| WO-2006028810-A2 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | claimed |
| CN-1585769-A | A2b adenosine receptor antagonists | CV THERAPEUTICS INC (US) | 2005-02-23 | — | — | CN | claimed |
| US-20050038045-A1 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-02-17 | — | — | US | claimed |
| US-6825349-B2 | PURINE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL DISORDERS, IMMUNOLOGICAL DISORDERS, NEUROLOGICAL DISORDERS | CV THERAPEUTICS INC. | 2004-11-30 | — | — | US | claimed |
| EP-1444233-A2 | A 2B? ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-08-11 | — | — | EP | claimed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | claimed |
| WO-2003042214-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-05-22 | — | — | WO | claimed |
| CN-110372626-B | Method for preparing 1,2, 4-oxadiazole compound | 河南大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-106279056-B | (5-aryl-1, 2, 4-oxadiazole-3-yl) (3,4, 5-trimethoxyphenyl) -methanol, -ketone oxime compound and application thereof | 沈阳药科大学 | 2019-12-10 | — | — | CN | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9371316-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140364462-A1 | PYRIDINE DERIVATIVES | ASANA BIOSCIENCES, LLC | 2014-12-11 | — | — | US | disclosed |
| EP-2760833-A1 | PYRIDINE DERIVATIVES | Endo Pharmaceuticals Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049559-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-8242103-B2 | Sulphamides for treatment of cancer | MERCK SHARP & DOHME LIMITED (GB) | 2012-08-14 | — | — | US | disclosed |
| EP-2311462-A1 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-7482448-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1885349-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | Merck Sharp & Dohme Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123185-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| US-7138400-B2 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1682524-A1 | NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1334085-B1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005040142-A9 | NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS | AVENTIS PHARMA INC (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005040142-A1 | NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | disclosed |
| EP-1334085-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LTD. (GB) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002036555-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036555-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073339-A1 | PYRIDINE DERIVATIVES | CYP21A2, CYP26A1, CYP11B1 | NPC1 2391/4885RAB9A 3120/4885NOTUM 2320/4885 |
| US-20050038045-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | NPC1 2104/4885RAB9A 1841/4885NOTUM 3708/4885 |
| US-20140364462-A1 | PYRIDINE DERIVATIVES | CYP21A2, CYP26A1, CYP11B1 | NPC1 2391/4885RAB9A 3120/4885NOTUM 2320/4885 |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | SDHA, SDHB, BRDT | NPC1 3909/4885RAB9A 3104/4885NOTUM 1384/4885 |
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | NPC1 2057/4885RAB9A 1699/4885NOTUM 3850/4885 |
| US-20100105706-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | NPC1 1966/4885RAB9A 2329/4885NOTUM 3625/4885 |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | NPC1 2360/4885RAB9A 3262/4885NOTUM 411/4885 |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | NPC1 4181/4885RAB9A 1909/4885NOTUM 4178/4885 |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSB, CTSS, CTSK | NPC1 59/4885RAB9A 419/4885NOTUM 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.